Atea Pharmaceuticals, Inc. (AVIR) — 分析师展望 / 分析师共识目标价为. 基于 4 位分析师评级, 共识为 中性 — 1 买入, 2 持有, 1 卖出.
分析师共识目标价为 $6.88, 上涨空间为 18.6% 相对于当前价格 $5.80.
分析师预估 每股收益(EPS)为 $-1.80 和 营收为 $0.07B (下一财年).
每股收益(EPS)历史表现: 2024: 实际 $-2.00 vs 预期 $-1.80 (不及预期 -10.9%). 2025: 实际 $-1.94 vs 预期 $-1.73 (不及预期 -12.5%). 分析师准确度: 90%.
AVIR 股票 — 12个月价格预测
$6.88
▲ +18.62% 上涨空间
平均目标价
Based on 4 Wall Street analysts offering 12-month price targets for Atea Pharmaceuticals, Inc., the price target is $6.88.
平均目标价相对最新价格 $5.80 变动 +18.62%。
AVIR 分析师评级
Hold
基于过去3个月内 4 位分析师对 Atea Pharmaceuticals, Inc. 的评级
EPS 预测 — AVIR
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.00
vs Est –$1.80
▼ 9.8% off
2025
Actual –$1.94
vs Est –$1.73
▼ 11.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
营收预测 — AVIR
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
